Loading...
  • Anti-CD20
  • One implication of these results is that the FO subset of B cells preferentially contributes to early diabetes initiation events.However, most important, the inefficient ability of anti-CD20 treatment to exert late-stage diabetes prevention was found to be attributable to downregulation of CD20 expression upon B cell entry into pancreatic islets.These findings provide important guidance for designing strategies targeting B cells as a potential means of diabetes intervention. (nih.gov)
  • Therefore, we tested the ability of anti-CD20 to prevent diabetes in NOD mice when administered either before or after IAA onset. (nih.gov)
  • However, most important, the inefficient ability of anti-CD20 treatment to exert late-stage diabetes prevention was found to be attributable to downregulation of CD20 expression upon B cell entry into pancreatic islets. (nih.gov)
  • Compared with controls, diabetes development was significantly decreased only in NOD mice treated with anti-CD20 alone (P = 0.0175, Kaplan-Meier analyses). (nih.gov)
  • While numerically increased, on a per cell basis, Treg functional activity in anti-CD20-treated NOD mice was equivalent to that in controls (Supplementary Fig. 4). (nih.gov)
  • We then tested if the elicited numerical increase in Tregs might contribute to the ability of anti-CD20 treatment to inhibit diabetes development when initiated in pre-IAA onset NOD mice. (nih.gov)
  • As expected, compared with controls, diabetes development was significantly reduced in NOD mice in which anti-CD20 treatment was initiated before IAA onset (Fig. 6). (nih.gov)
  • Hence, anti-CD25 coinfusions did not abrogate the diabetes protective effects of anti-CD20 treatment by eliciting alterations in pathogenic effector T-cell activity differing from in NOD control mice. (nih.gov)
  • targets
  • While activity of the retargeted NK-92 against CD20-negative targets remained unchanged, the gene modified NK cells displayed markedly enhanced cytotoxicity toward NK-sensitive CD20 expressing cells. (springer.com)
  • CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. (cancer.gov)
  • Researchers at the National Cancer Institute (NCI) have developed the current invention which is an expression construct for a CAR that targets both CD19 and CD20. (cancer.gov)
  • scFv
  • NK-92-scFv(Leu-16)-ζ cells were incubated with 100 μM of the serine protease inhibitor DCI (3,4-dichloroisocoumarin) (Roche, Mannheim, Germany) in X-VIVO 10 medium for 1 h at 37°C, before their cytotoxic activity towards CD20 expressing NIH3T3-CD20 cells was analyzed in a 3 h MTT cytotoxicity assay as described in the methods section (E/T ratio of 10:1). (springer.com)
  • gene
  • Isolation, tissue distribution, and chromosomal localization of a novel testis-specific human four-transmembrane gene related to CD20 and FcepsilonRI-beta. (ebi.ac.uk)
  • CHO-Anti-Human CD20 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CD20 F(ab) gene to allow expression of the F(ab). (creativebiomart.net)
  • therapeutic
  • The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ofatumumab. (drugbank.ca)
  • This suggests that a therapeutic with the ability to simultaneously target both CD19 and CD20 could represent a solution to the drawbacks of current therapies. (cancer.gov)
  • Efficacy
  • Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. (nih.gov)